Cell line development: The linchpin in successful biotherapeutic development

In this whitepaper from Abzena, the focus is on the expanding antibody-based biologics market, which is expected to grow rapidly, targeting various therapeutic areas. To efficiently deliver these biologics, a robust cell line development (CLD) strategy is suggested. CLD, as the foundation of drug manufacturing, requires a proactive approach to identify potential risks and challenges, ensuring timely development. A strong CLD strategy is highlighted for its ability to accelerate timelines by enabling parallel development activities and enhancing lead candidate selection through the generation of fast stable pools. The whitepaper emphasizes the importance of considering various factors in building a reliable CLD strategy, including access to experts, understanding downstream implications, and staying informed about applicable regulations.